RA Capital Management 13F holdings, Q4 2012
Holdings as of December 31, 2012 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 19 US equity positions worth $225.0m in its Q4 2012 13F filing. The largest position was ACAD at 16.7% of the reported book, followed by DYAX CORP and NVAX. Against the Q3 2012 filing, it opened 4 new positions, added to 8 and reduced 5 among the top 19 holdings.
What did RA Capital Management own in Q4 2012? Top 19 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2012 |
|---|---|---|---|---|---|---|---|
| 1 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 16.7% | $37.6m | 8,077,092 | 83% | added |
| 2 | DYAX CORP | 13.2% | $29.8m | 8,553,440 | 0% | held | |
| 3 | NVAX NOVAVAX INC | Healthcare | 12.2% | $27.4m | 14,511,748 | 10% | added |
| 4 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 10.2% | $22.9m | 3,802,925 | 78% | added |
| 5 | SUNESIS PHARMACEUTICALS INC | 9.1% | $20.4m | 4,858,551 | 88% | added | |
| 6 | DERMA SCIENCES INC | 7.8% | $17.5m | 1,573,931 | 26% | added | |
| 7 | XOMA CORP DEL | 7.0% | $15.7m | 6,549,454 | 112% | added | |
| 8 | ARTHROCARE CORP | 6.0% | $13.4m | 387,462 | -12% | reduced | |
| 9 | CORONADO BIOSCIENCES INC | 3.5% | $7.8m | 1,735,597 | -2% | reduced | |
| 10 | SENOMYX INC | 3.0% | $6.7m | 3,965,635 | 44% | added | |
| 11 | ILMN ILLUMINA INC | Healthcare | 3.0% | $6.7m | 119,700 | – | new |
| 12 | CHEMOCENTRYX INC | 2.7% | $6.1m | 555,509 | – | new | |
| 13 | CYTORI THERAPEUTICS INC | 2.6% | $5.9m | 2,105,200 | – | new | |
| 14 | VENTRUS BIOSCIENCES INC | 1.2% | $2.7m | 1,272,744 | 2% | added | |
| 15 | ANACOR PHARMACEUTICALS INC | 1.0% | $2.2m | 420,922 | -83% | reduced | |
| 16 | NEWLINK GENETICS CORP | 0.5% | $1.2m | 96,666 | – | new | |
| 17 | SYNERGY PHARMACEUTICALS DEL | 0.4% | $838.0k | 159,383 | -39% | reduced | |
| 18 | SAVIENT PHARMACEUTICALS INC | 0.1% | $180.0k | 1,000,000 | 0% | held | |
| 19 | TRANZYME INC | 0.1% | $114.0k | 210,800 | -55% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.